Physician profile
David E Bobman
NPI 1063471712
$8,834.31
in general payments reported to CMS, 2019-2025
39 companies · $1,350 in 2025
The $1,350 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $764 · 2020: $137 · 2021: $625 · 2022: $1,421 · 2023: $2,548 · 2024: $1,988 · 2025: $1,350.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,887.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,886.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,165.08 | 2019-2025 | Skyrizi, Rinvoq, Mavyret |
| Janssen Biotech, INC. | $1,063.14 | 2019-2025 | Stelara, Tremfya, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $836.30 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $652.30 | 2019-2025 | Xifaxan, Trulance |
| Celgene Corporation | $628.78 | 2021-2024 | Zeposia |
| Pfizer INC. | $488.35 | 2019-2025 | |
| Gilead Sciences, INC. | $256.66 | 2019-2025 | |
| Ferring Pharmaceuticals INC. | $232.41 | 2022-2025 | Rebyota |
| Intercept Pharmaceuticals, INC. | $227.78 | 2019-2023 | Ocaliva |
| Genzyme Corporation | $198.44 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $178.20 | 2019-2023 | Dificid |
| Ardelyx, INC. | $159.73 | 2022-2025 | Ibsrela |
| Ironwood Pharmaceuticals, INC | $151.21 | 2021-2023 | Linzess |
| Regeneron Healthcare Solutions, INC. | $150.66 | 2022-2025 | Dupixent |
| E.R. Squibb & Sons, L.L.C. | $142.80 | 2023 | Zeposia |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Qol Medical, LLC | $139.48 | 2021-2024 | Sucraid, Sucraid |
| Lilly USA, LLC | $135.32 | 2024-2025 | Omvoh |
| Madrigal Pharmaceuticals | $126.26 | 2024-2025 | Resmetirom, Rezdiffra |
| Ipsen Biopharmaceuticals, INC | $105.85 | 2024-2025 | Iqirvo, Bylvay |
| Amgen INC. | $105.23 | 2021-2023 | Avsola, Amjevita |
| Aimmune Therapeutics, INC. | $103.68 | 2024-2025 | Zenpep |
| Celltrion USA INC. | $78.75 | 2024-2025 | Vegzelma |
| Phathom Pharmaceuticals, INC. | $55.99 | 2024-2025 | Voquezna |
| Braintree Laboratories, INC. | $52.89 | 2022 | |
| Sandoz INC. | $47.35 | 2023-2024 | Hyrimoz |
| Vivus LLC | $46.31 | 2019-2020 | |
| Intra-Sana Laboratories | $39.12 | 2022-2025 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Shionogi INC | $34.64 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $34.25 | 2022 | |
| Nestle Healthcare Nutrition INC. | $27.45 | 2022 | |
| Organon LLC | $24.80 | 2023 | Renflexis, Hadlima |
| Ucb, INC. | $21.01 | 2019 | |
| Micro-Tech Endoscopy USA, INC. | $20.20 | 2023 | Lesion Hunter |
| Digestive Care, INC. | $20.16 | 2025 | Pertzye |
| Astrazeneca Pharmaceuticals LP | $19.59 | 2023 | Andexxa |
| Biohaven Pharmaceuticals, INC. | $19.22 | 2021 | |
| Alfasigma USA, INC. | $17.07 | 2020 | |
| Medtronic, INC. | $15.19 | 2021 | |
| Mauna Kea Technologies, INC. | $12.66 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Bobman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.